BACKGROUND: Acute hepatitis C has variable modes of presentation and frequently results in chronic infection. Its optimal management has yet to be defined. AIM: To establish natural history and complications of treatment of acute hepatitis C. METHODS: Data from all patients presenting with acute hepatitis C to the National Institutes of Health between 1994 and 2007 were reviewed. RESULTS: Twenty-five patients were identified. Symptoms were reported by 80% and jaundice by 40%. Aminotransferase levels and hepatitis C virus (HCV) RNA levels fluctuated greatly; 18% of patients were intermittently negative for HCV RNA. Five patients recovered spontaneously whereas 20 developed chronicity or received interferon-based therapy during the acute phase. Among 15 patients treated during the acute phase with peginterferon with or without ribavirin for 24 weeks, all became HCV RNA negative within 4-8 weeks, and all except two (HIV-positive) achieved a sustained virological response. Side effects (particularly psychiatric) were common and limited treatment in 30%. CONCLUSIONS: Among 25 patients with acute HCV infection, fluctuating illness was common and spontaneous recovery occurred in only 20%. Anti-viral treatment with a 24-week course of peginterferon and ribavirin was highly effective, but marked by frequent and severe side effects. Published 2010. This article is a US Government work and is in the public domain in the USA.
BACKGROUND:Acute hepatitis C has variable modes of presentation and frequently results in chronic infection. Its optimal management has yet to be defined. AIM: To establish natural history and complications of treatment of acute hepatitis C. METHODS: Data from all patients presenting with acute hepatitis C to the National Institutes of Health between 1994 and 2007 were reviewed. RESULTS: Twenty-five patients were identified. Symptoms were reported by 80% and jaundice by 40%. Aminotransferase levels and hepatitis C virus (HCV) RNA levels fluctuated greatly; 18% of patients were intermittently negative for HCV RNA. Five patients recovered spontaneously whereas 20 developed chronicity or received interferon-based therapy during the acute phase. Among 15 patients treated during the acute phase with peginterferon with or without ribavirin for 24 weeks, all became HCV RNA negative within 4-8 weeks, and all except two (HIV-positive) achieved a sustained virological response. Side effects (particularly psychiatric) were common and limited treatment in 30%. CONCLUSIONS: Among 25 patients with acute HCV infection, fluctuating illness was common and spontaneous recovery occurred in only 20%. Anti-viral treatment with a 24-week course of peginterferon and ribavirin was highly effective, but marked by frequent and severe side effects. Published 2010. This article is a US Government work and is in the public domain in the USA.
Authors: Kathleen E Corey; Andrew S Ross; Alysse Wurcel; Julian Schulze Zur Wiesch; Arthur Y Kim; Georg M Lauer; Raymond T Chung Journal: Clin Gastroenterol Hepatol Date: 2006-08-22 Impact factor: 11.382
Authors: Johannes Wiegand; Peter Buggisch; Wulf Boecher; Stefan Zeuzem; Cornelia M Gelbmann; Thomas Berg; Wolfgang Kauffmann; Birgit Kallinowski; Markus Cornberg; Elmar Jaeckel; Heiner Wedemeyer; Michael P Manns Journal: Hepatology Date: 2006-02 Impact factor: 17.425
Authors: Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch Journal: J Infect Dis Date: 2009-10-15 Impact factor: 5.226
Authors: J Tilman Gerlach; Helmut M Diepolder; Reinhart Zachoval; Norbert H Gruener; Maria-Christina Jung; Axel Ulsenheimer; Winfried W Schraut; C Albrecht Schirren; M Waechtler; M Backmund; Gerd R Pape Journal: Gastroenterology Date: 2003-07 Impact factor: 22.682
Authors: Sanaa M Kamal; Alaa Ismail; Camilla S Graham; Qi He; Jens W Rasenack; Thomas Peters; Ahmed A Tawil; Jutta J Fehr; Khalifa El Sayed Khalifa; Mahmoud M Madwar; Margaret James Koziel Journal: Hepatology Date: 2004-06 Impact factor: 17.425
Authors: Maria Kalafateli; Elena Buzzetti; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy Journal: Cochrane Database Syst Rev Date: 2017-03-13
Authors: Behzad Hajarizadeh; Jason Grebely; Tanya Applegate; Gail V Matthews; Janaki Amin; Kathy Petoumenos; Margaret Hellard; William Rawlinson; Andrew Lloyd; John Kaldor; Gregory J Dore Journal: J Med Virol Date: 2014-07-08 Impact factor: 2.327
Authors: R Monina Klevens; Stephen Liu; Henry Roberts; Ruth B Jiles; Scott D Holmberg Journal: Am J Public Health Date: 2014-01-16 Impact factor: 9.308